GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (NAS:IGMS) » Definitions » PB Ratio

IGM Biosciences (IGM Biosciences) PB Ratio : 2.85 (As of May. 03, 2024)


View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-03), IGM Biosciences's share price is $9.87. IGM Biosciences's Book Value per Share for the quarter that ended in Dec. 2023 was $3.46. Hence, IGM Biosciences's PB Ratio of today is 2.85.

The historical rank and industry rank for IGM Biosciences's PB Ratio or its related term are showing as below:

IGMS' s PB Ratio Range Over the Past 10 Years
Min: 0.95   Med: 2.31   Max: 5.01
Current: 2.85

During the past 7 years, IGM Biosciences's highest PB Ratio was 5.01. The lowest was 0.95. And the median was 2.31.

IGMS's PB Ratio is ranked worse than
53.73% of 1312 companies
in the Biotechnology industry
Industry Median: 2.48 vs IGMS: 2.85

During the past 12 months, IGM Biosciences's average Book Value Per Share Growth Rate was -48.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -33.80% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of IGM Biosciences was -5.40% per year. The lowest was -33.80% per year. And the median was -19.60% per year.

Back to Basics: PB Ratio


IGM Biosciences PB Ratio Historical Data

The historical data trend for IGM Biosciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences PB Ratio Chart

IGM Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial 4.84 7.39 3.89 2.55 2.40

IGM Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 2.48 1.88 1.92 2.40

Competitive Comparison of IGM Biosciences's PB Ratio

For the Biotechnology subindustry, IGM Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IGM Biosciences's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGM Biosciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where IGM Biosciences's PB Ratio falls into.



IGM Biosciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

IGM Biosciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=9.87/3.463
=2.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


IGM Biosciences  (NAS:IGMS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


IGM Biosciences PB Ratio Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IGM Biosciences (IGM Biosciences) Business Description

Traded in Other Exchanges
Address
325 East Middlefield Road, Mountain View, CA, USA, 94043
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Executives
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Fred Schwarzer director, officer: CEO and President 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Bruce Keyt officer: Chief Scientific Officer 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Lisa Lynn Decker officer: Chief Business Officer C/O ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
George Gauthier officer: Chief Commercial Officer C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Chris H Takimoto officer: Chief Medical Officer C/O IGM BIOSCIENCES, INC., 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Misbah Tahir officer: Chief Financial Officer 325 E. MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Thompson Elizabeth H.z. director C/O HORIZON THERAPEUTICS, INC., 2 TOWER PLACE, 12TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Christina Teng Topsoe director, 10 percent owner 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Jakob Haldor Topsoe director, 10 percent owner 325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW CA 94043
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Michael D Loberg director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Steven Weber officer: Principal Accounting Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Baker Bros. Advisors (gp) Llc director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014